Gastroenterol Res

Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access

Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc

Journal website http://www.gastrores.org

Original Article

Volume 4, Number 6, December 2011, pages 262-267

Helicobacter Pylori DNA in Liver Tissues From Chronic Hepatitis C Egyptian Patients

Figure 1. Amplification of a 480-bp 16S rRNA DNA fragment of Helicobacter. Lane M: molecular size marker (100 - 1000 bp); lane 2, 4, 5: positive samples; lane 6: negative control (double-distilled water).

**Table 1.** Characteristics of the Chronic Hepatitis C Patients
Variables	N = 52
^*mean ± SD; ^# median (range);^¶ number (%).
Age (year)^*	42.5 ± 7.4
Gender^¶
Males	39 (75)
Females	13 (25)
ALT (IU/L)^*	56.8 ± 32.5
AST (IU/L)^*	50.7 ± 24.7
Albumin (g/dL)^*	4.3 ± 0.51
Direct Bilirubin (mg/dL)^*	0.27 ± 0.14
Total Bilirubin (mg/dL)^*	0.72 ± 0.26
AFP (ng/ml)^#	2.5 (0.1-33.7)
Hepatitis C Viral load (IU/mL)^#	165 000 (4 320 - 3 520 000)
Anti-schistosomal Ab + ve^¶	5 (9.6)
Fibrosis score
Low	37 (71%)
High	15 (29%)

Table 1. Characteristics of the Chronic Hepatitis C Patients

Variables

N = 52

^*mean ± SD; ^# median (range);^¶ number (%).

Age (year)^*

42.5 ± 7.4

Gender^¶

Males

39 (75)

Females

13 (25)

ALT (IU/L)^*

56.8 ± 32.5

AST (IU/L)^*

50.7 ± 24.7

Albumin (g/dL)^*

4.3 ± 0.51

Direct Bilirubin (mg/dL)^*

0.27 ± 0.14

Total Bilirubin (mg/dL)^*

0.72 ± 0.26

AFP (ng/ml)^#

2.5 (0.1-33.7)

Hepatitis C Viral load (IU/mL)^#

165 000 (4 320 - 3 520 000)

Anti-schistosomal Ab + ve^¶

5 (9.6)

Fibrosis score

Low

37 (71%)

High

15 (29%)

**Table 2.** Comparison Between Anti-*H. pylori* IgG Positive and Negative Patients Regarding Demographic and Laboratory Data
	Anti-H.pylori IgG + ve (n = 31)	Anti-H.pylori IgG - ve (n = 21)	P-value
^amean ± SD; ^bnumber (%); ^cmedian (range).
Age (year)^a	42.3 ± 6.9	42.9 ± 8.2	0.78
Gender^b
Male	24(77.4)	15 (71.4)
Female	7(22.6)	6 (28.6)	0.75
ALT (IU/L)^a	56.4 ± 27.5	57.4 ± 39.4	0.91
AST (IU/L)^a	49.3 ± 20.7	52.8 ± 30.2	0.62
Albumin (g/dL)^a	4.3 ± 0.5	4.4 ± 0.5	0.48
Direct bilirubin (mg/dL)^a	0.25 ± 0.13	0.31 ± 0.15	0.13
Total bilirubin (mg/dL)^a	0.72 ± 0.30	0.74 ± 0.2	0.79
AFP (ng/ml)^c	2.9 (0.5 - 32.9)	2 (0.1 - 33.7)	0.48
HCV Viral load (IU/mL)^c	95 700 (4 350 – 3 520 000)	225 000 (12 800 – 2 688 483)	0.18
Anti-schistosomal Ab + ve^b	3 (9.7)	2 (9.5)	0.64
Fibrosis Scoring^b
Low stage	21 (67.7)	16 (76.2)
High stage	10 (32.3)	5 (23.8)	0.51

Table 2. Comparison Between Anti-H. pylori IgG Positive and Negative Patients Regarding Demographic and Laboratory Data

Anti-H.pylori IgG + ve (n = 31)

Anti-H.pylori IgG - ve (n = 21)

P-value

^amean ± SD; ^bnumber (%); ^cmedian (range).

Age (year)^a

42.3 ± 6.9

42.9 ± 8.2

0.78

Gender^b

Male

24(77.4)

15 (71.4)

Female

7(22.6)

6 (28.6)

0.75

ALT (IU/L)^a

56.4 ± 27.5

57.4 ± 39.4

0.91

AST (IU/L)^a

49.3 ± 20.7

52.8 ± 30.2

0.62

Albumin (g/dL)^a

4.3 ± 0.5

4.4 ± 0.5

0.48

Direct bilirubin (mg/dL)^a

0.25 ± 0.13

0.31 ± 0.15

0.13

Total bilirubin (mg/dL)^a

0.72 ± 0.30

0.74 ± 0.2

0.79

AFP (ng/ml)^c

2.9 (0.5 - 32.9)

2 (0.1 - 33.7)

0.48

HCV Viral load (IU/mL)^c

95 700 (4 350 – 3 520 000)

225 000 (12 800 – 2 688 483)

0.18

Anti-schistosomal Ab + ve^b

3 (9.7)

2 (9.5)

0.64

Fibrosis Scoring^b

Low stage

21 (67.7)

16 (76.2)

High stage

10 (32.3)

5 (23.8)

0.51

**Table 3.** Comparison Between *H. pylori* DNA Positive and Negative Patients Regarding Demographic and Laboratory Data
	H.Pylori DNA + ve (n = 6)	H.Pylori DNA – ve (n = 46)	P-value
^amean ± SD; ^bnumber (%); ^cmedian (range).
Age (year)^a	45.6 ± 5.8	42.1 ± 7.5	0.28
Gender^b
Male	5 (83.3)	34 (74)
Female	1 (16.7)	12 (26)	1.0
ALT (IU/L)^a	64.3 ± 42.3	55.9 ± 31.5	0.56
AST (IU/L)^a	57 ± 24.7	49.9 ± 24.9	0.51
Albumin (g/dL)^a	4.6 ± 0.4	4.3 ± 0.5	0.17
Direct bilirubin (mg/dL)^a	0.25 ± 0.14	0.28 ± 0.15	0.65
Total bilirubin (mg/dL)^a	0.9 ± 0.47	0.7 ± 0.22	0.078
AFP (ng/mL)^c	3.5 (0.5 - 32.9)	2.2 (0.1 - 33.7)	0.75
HCV Viral load (IU/mL)^c	337 000 (51 200 - 3 520 000)	165 000 (4 320 – 2 688 483)	0.40
Fibrosis Scoring^b
Low stage	1 (16.7)	36 (78.3)
High stage	5 (83.3)	10 (21.7)	0.0057

Table 3. Comparison Between H. pylori DNA Positive and Negative Patients Regarding Demographic and Laboratory Data

H.Pylori DNA + ve (n = 6)

H.Pylori DNA – ve (n = 46)

P-value

^amean ± SD; ^bnumber (%); ^cmedian (range).

Age (year)^a

45.6 ± 5.8

42.1 ± 7.5

0.28

Gender^b

Male

5 (83.3)

34 (74)

Female

1 (16.7)

12 (26)

1.0

ALT (IU/L)^a

64.3 ± 42.3

55.9 ± 31.5

0.56

AST (IU/L)^a

57 ± 24.7

49.9 ± 24.9

0.51

Albumin (g/dL)^a

4.6 ± 0.4

4.3 ± 0.5

0.17

Direct bilirubin (mg/dL)^a

0.25 ± 0.14

0.28 ± 0.15

0.65

Total bilirubin (mg/dL)^a

0.9 ± 0.47

0.7 ± 0.22

0.078

AFP (ng/mL)^c

3.5 (0.5 - 32.9)

2.2 (0.1 - 33.7)

0.75

HCV Viral load (IU/mL)^c

337 000 (51 200 - 3 520 000)

165 000 (4 320 – 2 688 483)

0.40

Fibrosis Scoring^b

Low stage

1 (16.7)

36 (78.3)

High stage

5 (83.3)

10 (21.7)

0.0057